Following this transaction David Schenkein’s holding in the company was increased by 2.05% to a total of $31.52 million.
Based on Agios Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $40.41 million and GAAP net loss of $68.75 million. In comparison, last year the company earned revenue of $11.35 million and had a GAAP net loss of $83.08 million. Currently, Agios Pharma has an average volume of 313.5K.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $106.75, reflecting a 47.1% upside. Five different firms, including Canaccord Genuity and Cowen & Co., currently also have a Buy rating on the stock.
The insider sentiment on Agios Pharma has been positive according to 71 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.